

A Simple Route to *N*- ω -Chloroalkylisatins from Cyclic *t*-Anilines, Oxalyl Chloride and DABCO

Ying Cheng,*^a Yu-Hua Zhan,^a Otto Meth-Cohn*^b

^a Chemistry Department, Beijing Normal University, Beijing 100875, China
E-mail: yincheng@public2east.net.cn

^b Chemistry Department, University of Sunderland, Sunderland SR1 3SD, U.K.
E-mail: otto.meth-cohn@sunderland.ac.uk

Received 7 September 2001; revised 29 October 2001


Abstract: *para*-Substituted *N*-phenylpyrrolidines, -piperidines, -perhydroazepines and -morpholines react with oxalyl chloride and DABCO to give the pharmaceutically useful intermediates, *N*- ω -haloalkylisatins, under mild conditions and generally good yields.

Key words: cyclic *t*-anilines, oxalyl chloride, DABCO, *N*- ω -haoalkylisatins

N-ω-Haloalkylisatins **1** are important intermediates in the syntheses of pharmacologically important isatin derivatives. These include anaphylactic asthma inhibitors **2**,¹ gastroduodenal ulcer inhibitors **3**,² cholinesterase inhibitors **4**,³ and acetylcholinesterase inhibitors **5**,⁴ (which are useful in the treatment of neurodegenerative and cognitive dysfunction conditions such as Alzheimer's disease) and compounds **6**,⁵ used in treating central nervous system disorder (Figure).

Methods for the synthesis of the *N*- ω -haloalkylisatins^{1,4,6} are limited to the monoalkylation of isatins by dihaloalkanes. This method has serious limitations due to the lack of available isatins as starting materials and to poor yields due to side-reactions. Very recently, we reported⁷ that 5-substituted *N*-methylisatins **9** could be prepared in high

yield from *para*-substituted *N,N*-dimethylanilines **7** and oxalyl chloride (**8**), catalysed by DABCO (Scheme 1), via *o*-oxylation, ring-closure and demethylation.



Scheme 1

We have now discovered that this method is also applicable to *para*-substituted *N*-phenylheterocycles such as pyrrolidines, piperidines, morpholines and perhydroazepines **10–13**, with ring-opening of the heterocycle to give 5-substituted *N*- ω -chloroalkylisatins **17–20** as the sole products. The formation of **17–20** can be explained by a similar mechanism to that invoked for the formation of *N*-methylisatins **9⁷** (Scheme 2).

N-Methylisatins were prepared using DABCO in refluxing chloroform under nitrogen. The reactions of *para*-substituted *N*-phenylheterocycles **10–13** with the oxalyl




Figure Some pharmacologically important isatin derivatives **1–6**

Synthesis 2002, No. 1, 28–122001. Article Identifier:
1437-210X,E;2002,0,01,0034,0038,ftx,en;E06001SS.pdf.
© Georg Thieme Verlag Stuttgart · New York
ISSN 0039-7881


chloride/DABCO salt **14** required long reaction times and/or gave poor yields under these conditions, while with acetonitrile as the solvent, the reaction temperature and

time were decreased significantly. Furthermore, the yield of products, particularly when the *para*-substituted *N*-acetonitrile as the solvent, the reaction temperature and

Table 1 Reactions Between *para*-Substituted *N*-Phenylheterocycles and Oxalyl Chloride/DABCO

<i>N</i> -Phenyl-Hetero- cycle	Solvent	Temp (°C)	Time (h)	Product ^a	Yield(%)	Mp (°C)
10a	CH ₂ Cl ₂	70	10	17a	79	79–80
10a	MeCN	30	2	17a	81	
10b	CHCl ₃	64	10	17b	60	86–87
10b	toluene	90–100	46	17b	37	
10b	MeCN	30	6	17b	72	
10c	CHCl ₃	35	11	17c	41	90–92
10c	MeCN	35	5	17c	44	
10d	CHCl ₃	64	11	17d	37	85–86
10d	Cl ₂ CHCHCl ₂	110	23	17d	48	
10d	MeCN	80–85	9	17d	37	
10e	ClCH ₂ CH ₂ Cl	82	47	17e	36	77–78
10e	MeCN	82	10	17e	40	
11a	CHCl ₃	64	16	18a	48	48–50
11a	MeCN	60	11	18a	59	
11b	CHCl ₃	64	19	18b	35	95–97
11b	MeCN	60	11	18b	44	
11d	CHCl ₃	64	40	18d	27	84–86
11d	MeCN	65	11	18d	30	
12a	CHCl ₃	64	8	19a	50	45–47
12a	MeCN	48	11	19a	52	
12b	ClCH ₂ CH ₂ Cl	85	16	19b	42	69–71
12b	MeCN	65	11	19b	42	
12d	CHCl ₃	64	24	19d	16	70–72
12d	MeCN	65	11	19d	33	
13a	CHCl ₃	64	18	20a	25	74–76
13a	MeCN	56	11	20a	47	
13b	CHCl ₃	64	38	20b	22	87–89
13b	MeCN	58	10	20b	52	
13c	CHCl ₃	64	48	20c	0	–
13d	CHCl ₃	64	48	20d	0	170–171
13d	MeCN	85	20	20d	9	
13e	MeCN	82	11	20e	8	113–114

^a Satisfactory microanalyses obtained: C ±0.34, H ±0.35, N ±0.36. Exceptions: **17b**, C –0.68; **18b**, C –0.47; **20a**, C –0.47.



	Z	CH ₂	CH ₂ CH ₂	O
OCH ₃	10a	11a	12a	13a
	17a	18a	19a	20a
CH ₃	10b	11b	12b	13b
	17b	18b	19b	20b
F	10c			
	17c			
Cl	10d	11d	12d	13d
	17d	18d	19d	20d
Br	10e			13e
	17e			20e

Scheme 2

phenylmorpholines were utilised, was improved (Table 1).

Methoxy- and methyl-substituted *t*-anilines **10–13** gave higher yields of isatins than their halogen substituted analogues, probably due to the electron-withdrawing effect of the latter substituents on the oxaryl-ring-closure and ring-opening reactions. However, the fluoro-substituted *t*-aniline **10c** was more reactive than the chloro- or bromo-substituted analogues indicating that the reaction sequences are not so trivially explained. If the reaction of fluoro derivative **10c** with oxaryl chloride was carried out above 60 °C, the reaction mixture became very dark. The conversions of the halo *t*-anilines **10d** and **10c** into isatins were not complete even after long reaction times.

The pyrrolidines **10** gave the highest yields of isatins compared to their piperidine **11**, perhydroazepine **12**, and morpholine **13** analogues due probably to the easier ring-opening of the strained spiro-5,5-intermediate. Combination of these two effects, as expected, resulted in the high-

est yield of isatin from *N*-(*p*-methoxyphenyl)pyrrolidine (81%), while the *N*-(*p*-halophenyl)morpholines gave the lowest yields.

We believe that this method is the simplest route for the preparation of *N*-chloroalkylisatins, requiring only simple, cheap starting materials and reagents, and mild conditions.

Melting points or boiling points and pressure are uncorrected. ¹H NMR and ¹³C NMR were obtained on a Bruker Avance 500. IR spectra were recorded using a Avatar 360 FT-IR spectrometer. Mass spectra were recorded on a KYKY-ZHT-5 instrument and elemental analyses were performed on a GMBH Vario EL instrument.

para-Substituted *N*-Phenylheterocycles **10–13**; General Procedure

To a solution of **7** (50 mmol) in anhyd toluene (20 mL) were added *N,N*-diisopropylethylamine (1.42 g, 11 mmol) and a dibromoalkane (55 mmol) (The BrCH₂CH₂OCH₂CH₂Br was displaced by TsOCH₂CH₂OCH₂CH₂OTs when *para*-substituted *N*-phenylmorpholines were prepared). The mixture was refluxed for 18–24 h under N₂. After cooling, the mixture was poured into H₂O (100 mL) and the toluene layer was separated. The aqueous solution was extracted with Et₂O (3 × 50 mL) and the organic layers were combined and dried (MgSO₄). After removal of the solvent, the product was obtained by distillation or chromatography on silica gel eluting with variable amounts of hexane–EtOAc (Table 2).

Table 2 *para*-Substituted *N*-Phenylheterocycles **10–13** Prepared

Product	Yield (%)	Mp (°C) or Bp (°C)/Torr	Found	Reported
10a	83	45–46	46–47 ⁸	
10b	80	38–40	39–40 ⁹	
10c	61	58–60/0.2	122/13 ¹⁰	
10d	64	85–87	85–86 ¹¹	
10e	78	103–105	103 ¹²	
11a	79	77–79/0.15	37 ^{13,a}	
11b	86	97–98/1	57–60/0.5 ⁹	
11d	74	68–71	69 ¹⁴	
12a	23	94–96/0.3	87/0.2 ¹⁵	
12b	30	76–80/0.2	62/0.12 ¹⁵	
12d	24	84–85/0.3	75/0.2 ¹⁵	
13a	54	71–73	71–73 ¹⁶	
13b	70	95/0.5 ^b	91/0.4 ¹⁷	
13d	45	71–73	71–72 ¹⁸	
13e	55	115–117	112–113 ¹⁹	

^a Melting point.

^b Melting point 44–45 °C.

***N*- ω -Chloroalkylisatins 17–20; General Procedure**

Oxalyl chloride (1.75 mL, 2.55 g, 20 mmol) was added dropwise to a solution of DABCO (11 mmol) in the appropriate solvent (10 mL) (see Table 1) cooled in an ice-bath under N_2 to form a pale yellow solid salt. To this salt was added slowly with ice-bath cooling, the *para*-substituted *N*-phenylheterocycle **10** (10 mmol) in the same solvent (50 mL) and the mixture was stirred for the period of time and at the temperature shown in Table 1. After removal of solvent,

the residue was neutralized with 10% aq NaHCO_3 . The products were extracted with CHCl_3 (3×100 mL) and dried (MgSO_4). After removal of solvent, the isatins were purified by chromatography on silica gel, eluting with variable amounts of hexane–EtOAc (Table 3).

Table 3 Spectroscopic Data of Isatins 17–20

Product	IR ν (cm $^{-1}$)	^1H NMR (CDCl_3/TMS) δ , J (Hz)	^{13}C NMR (CDCl_3/TMS) δ	MS (EI) (rel. intensity, %)
17a	1730, 1616, 1599, 1490	7.18 (1 H, s), 7.17 (1 H, d, J = 7.6), 6.87 (1 H, d, J = 7.9), 3.84 (3 H, s, OCH_3), 3.77 (2 H, t, J = 6.5, NCH_2), 3.63 (2 H, t, J = 5.8, CH_2Cl), 1.90 (4 H, m, CH_2CH_2)	184.2, 158.7, 157.0, 145.0, 125.1, 118.5, 111.5, 110.2, 56.4, 44.6, 39.7, 29.9, 24.9	149 (95), 162 (100), 176 (39), 177 (38), 267 (M^+ , 60)/269 (20)
17b	1739, 1621, 1594, 1490	7.44 (1 H, s), 7.42 (1 H, d, J = 8.2), 6.84 (1 H, d, J = 8.0), 3.77 (2 H, t, J = 6.5, NCH_2), 3.62 (2 H, t, J = 5.9, CH_2Cl), 2.36 (3 H, s, CH_3), 1.89 (4 H, m, CH_2CH_2)	184.0, 158.7, 148.9, 139.2, 134.0, 126.3, 118.1, 110.3, 44.6, 39.7, 29.9, 24.9, 21.0	133 (100), 146 (90), 160 (37), 251 (M^+ , 60)/253 (20)
17c	1741, 1728, 1618, 1606, 1485, 1464	7.29–7.37 (2 H, m), 6.91–6.94 (2 H, m), 3.79 (2 H, t, J = 6.6, NCH_2), 3.63 (2 H, t, J = 5.9, CH_2Cl), 1.89 (4 H, m, CH_2CH_2)	183.1, 160.7, 158.7, 158.4, 147.1, 125.2, 125.0, 118.7, 113.1, 112.9, 111.7, 111.6, 44.5, 39.9, 29.8, 24.8	137 (37), 150 (100), 255 (M^+ , 9)/257 (3)
17d	1751, 1735, 1605, 1592, 1474, 1445	7.61 (1 H, s), 7.60 (1 H, d, J = 10.8), 6.91 (1 H, d, J = 8.2), 3.80 (2 H, t, J = 6.5, NCH_2), 3.63 (2 H, t, J = 5.8, CH_2Cl), 1.91 (4 H, m, CH_2CH_2)	182.7, 158.1, 149.3, 138.2, 130.1, 125.9, 118.9, 111.8, 44.5, 39.9, 29.8, 24.8	153 (85), 166 (100)/168 (55), 180 (22), 271 (M^+ , 7)/273 (4)/ 275 (2)
17e	1735, 1599, 1472, 1441	7.74 (2 H, m), 6.86 (1 H, d, J = 8.9), 3.79 (2 H, t, J = 6.5, NCH_2), 3.62 (2 H, t, J = 5.8, CH_2Cl), 1.89 (4 H, m, CH_2CH_2)	182.5, 157.9, 149.8, 141.0, 128.7, 119.2, 117.0, 112.2, 44.5, 39.9, 29.8, 24.8	197 (100)/199 (80), 210 (75)/ 212 (73), 315 (M^+ , 9)/317 (10)/319 (4)
18a	1747, 1722, 1632, 1595, 1491, 1470	7.16 (1 H, s), 7.15 (1 H, dd, J = 8.2, 2.7), 6.81 (1 H, d, J = 8.2), 3.81 (3 H, s, OCH_3), 3.71 (2 H, t, J = 7.2, NCH_2), 3.54 (2 H, t, J = 6.5, CH_2Cl), 1.83 (2 H, m, CH_2), 1.73 (2 H, m, CH_2), 1.53 (2 H, m, CH_2)	184.2, 158.6, 156.9, 145.1, 125.0, 118.5, 111.5, 110.2, 56.4, 45.0, 40.4, 32.4, 27.0, 24.5	149 (60), 162 (100), 176 (50), 177 (49), 190 (75), 218 (80), 281 (83)/283 (53)
18b	1737, 1725, 1620, 1597, 1492	7.44 (1 H, s), 7.41 (1 H, d, J = 8.0), 6.81 (1 H, d, J = 8.0), 3.74 (2 H, t, J = 7.2, NCH_2), 3.56 (2 H, t, J = 6.5, CH_2Cl), 2.36 (3 H, s, CH_3), 1.86 (2 H, m, CH_2), 1.76 (2 H, m, CH_2), 1.56 (2 H, m, CH_2)	184.1, 158.7, 149.1, 139.1, 133.9, 126.5, 118.1, 110.3, 45.0, 40.3, 32.4, 27.0, 24.5, 21.0	146 (100), 175 (24), 265 (M^+ , 15)/267 (5)
18d	1752, 1735, 1605, 1475, 1446	7.59 (1 H, s), 7.58 (1 H, d, J = 9.2), 6.89 (1 H, d, J = 8.1), 3.76 (2 H, t, J = 7.2, NCH_2), 3.56 (2 H, t, J = 6.5, CH_2Cl), 1.86 (2 H, m, CH_2), 1.75 (2 H, m, CH_2), 1.56 (2 H, m, CH_2)	182.9, 158.0, 149.5, 138.1, 130.0, 125.9, 118.8, 111.7, 45.0, 40.6, 32.3, 26.9, 24.5	166 (100)/168 (40), 285 (M^+ , 9)/287 (7)/289 (2)
19a	1732, 1618, 1598, 1491	7.17 (1 H, s), 7.16 (1 H, d, J = 7.3), 6.83 (1 H, d, J = 8.9), 3.83 (3 H, s, OCH_3), 3.72 (2 H, t, J = 7.2, NCH_2), 3.52 (2 H, t, J = 6.5, CH_2Cl), 1.80 (2 H, m, CH_2), 1.74 (2 H, m, CH_2), 1.52 (2 H, m, CH_2), 1.42 (2 H, m, CH_2)	184.4, 158.6, 156.8, 145.2, 125.1, 118.4, 111.5, 110.1, 56.4, 45.3, 40.5, 32.7, 27.5, 26.8, 26.6	149 (35), 162 (100), 177 (40), 295 (M^+ , 16)/297 (10)
19b	1744, 1725, 1619, 1596, 1491	7.43 (1 H, s), 7.41 (1 H, d, J = 8.1), 6.81 (1 H, d, J = 8.0), 3.73 (2 H, t, J = 7.3, NCH_2), 3.55 (2 H, t, J = 6.6, CH_2Cl), 2.36 (3 H, s, CH_3), 1.79 (2 H, m, CH_2), 1.73 (2 H, m, CH_2), 1.52 (2 H, m, CH_2), 1.42 (2 H, m, CH_2)	184.2, 158.7, 149.2, 139.1, 133.9, 126.2, 118.1, 110.3, 45.3, 40.4, 32.8, 27.6, 26.8, 26.6, 21.0	133 (54), 146 (100), 175 (45), 279 (M^+ , 45)/281 (15)

Table 3 Spectroscopic Data of Isatins **17–20** (continued)

Product	IR ν (cm^{-1})	^1H NMR (CDCl_3/TMS) δ, J (Hz)	^{13}C NMR (CDCl_3/TMS) δ	MS (EI) (rel. intensity, %)
19d	1752, 1731, 1608, 1589, 1473, 1447	7.57 (1 H, s), 7.56 (1 H, d, $J = 8.6$), 6.86 (1 H, d, $J = 8.2$), 3.73 (2 H, t, $J = 7.2$, NCH_2), 3.53 (2 H, t, $J = 6.5$, CH_2Cl), 1.78 (2 H, m, CH_2), 1.72 (2 H, m, CH_2), 1.51 (2 H, m, CH_2), 1.41 (2 H, m, CH_2)	182.9, 158.0, 149.6, 138.1, 129.9, 125.8, 118.8, 111.7, 45.2, 40.6, 32.7, 27.5, 26.8, 26.5	153 (40), 166 (100)/168 (40), 299 (M^+ , 12)/301 (5)/303 (2)
20a	1730, 1616, 1601, 1491	7.12 (1 H, s), 7.13 (1 H, d, $J = 9.1$), 7.03 (1 H, d, $J = 8.3$), 3.91 (2 H, t, $J = 5.1$, OCH_2), 3.81 (3 H, s, OCH_3), 3.77 (2 H, t, $J = 5.1$, NCH_2), 3.71 (2 H, t, $J = 5.5$, OCH_2), 3.56 (2 H, t, $J = 5.5$, CH_2Cl)	184.1, 159.0, 156.8, 145.9, 125.2, 118.3, 113.0, 109.4, 71.5, 69.4, 56.4, 43.3, 40.9	162 (100), 177 (20), 283 (M^+ , 10)/285 (4)
20b	1743, 1729, 1618, 1598, 1492	7.39 (1 H, s), 7.38 (1 H, d, $J = 9.7$), 6.99 (1 H, d, $J = 7.9$), 3.92 (2 H, t, $J = 5.1$, OCH_2), 3.78 (2 H, t, $J = 5.1$, NCH_2), 3.71 (2 H, t, $J = 5.5$, OCH_2), 3.56 (2 H, t, $J = 5.5$, CH_2Cl), 2.33 (3 H, s, CH_3)	184.0, 159.0, 149.7, 139.1, 133.9, 125.8, 118.0, 111.6, 71.6, 69.2, 43.2, 40.8, 21.0	146 (100), 161 (23), 267 (M^+ , 17)/269 (7)
20d	1750, 1731, 1607, 1475, 1448	7.57 (1 H, s), 7.56 (1 H, d, $J = 7.9$), 7.13 (1 H, d, $J = 8.5$), 3.96 (2 H, t, $J = 4.9$, OCH_2), 3.80 (2 H, t, $J = 5.1$, NCH_2), 3.73 (2 H, t, $J = 5.2$, OCH_2), 3.60 (2 H, t, $J = 5.6$, CH_2Cl)	182.8, 158.4, 150.3, 138.1, 129.9, 125.3, 118.7, 113.5, 71.6, 69.6, 43.3, 41.2	107 (70), 166 (10), 168 (80), 181 (80)/183 (45), 287 (M^+ , 50)/289 (34)/291 (6)
20e	1747, 1731, 1604, 1473, 1440	7.71 (1 H, s), 7.70 (1 H, d, $J = 7.2$), 7.09 (1 H, d, $J = 9.0$), 3.96 (2 H, t, $J = 5.0$, OCH_2), 3.80 (2 H, t, $J = 5.0$, NCH_2), 3.73 (2 H, t, $J = 5.2$, OCH_2), 3.58 (2 H, t, $J = 5.5$, CH_2Cl)	182.6, 158.2, 150.7, 140.9, 128.2, 119.0, 116.9, 113.9, 71.6, 69.5, 43.3, 41.2	107 (80), 155 (60)/157 (55), 210 (100)/212 (98), 225 (85)/227 (82), 331 (M^+ , 52)/333 (60)/335 (20)

Acknowledgement

This work was supported by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry, China.

References

- (1) Teraji, T.; Oku, T.; Namiki, T. Eur. Patent 10398, **1980**; *Chem. Abstr.* **1980**, *93*, 220773.
- (2) Kobayashi, M.; Kitazawa, M. Y. Japanese Patent 62270576, **1987**; *Chem. Abstr.* **1988**, *109*, 110263.
- (3) Boar, B. R.; Cross, A. J. WO Patent 9312085, **1993**; *Chem. Abstr.* **1993**, *119*, 225964.
- (4) Boar, B. R.; O'shea, D. M.; Tomlinson, I. D. WO Patent 9429272, **1994**; *Chem. Abstr.* **1995**, *122*, 239179.
- (5) Gallagher, P. T.; Owton, W. M.; Smith, C. W. Eur. Patent 780388, **1997**; *Chem. Abstr.* **1997**, *127*, 135719.
- (6) Rekhter, M. A.; Radul, O. M.; Bukhanyuk, S. M. *Chem. Heterocycl. Compd. (Engl. Trans.)* **1999**, *35*, 792.
- (7) Cheng, Y.; Ye, H. L.; Zhan, Y. H.; Meth-Cohn, O. *Synthesis* **2001**, 904.
- (8) Venuti, M. C.; Ort, O. *Synthesis* **1988**, 985.
- (9) Juaristi, E.; Madrigal, D. *Tetrahedron* **1989**, *45*, 629.
- (10) Sellers, C.; Suschitzky, H. *J. Chem. Soc.* **1965**, 6186.
- (11) Shim, S. C.; Huh, K. T.; Park, W. H. *Tetrahedron* **1986**, *42*, 259.
- (12) Beach, S. F.; Hepworth, J. D.; Sawyer, J.; Hallas, G.; Marsden, R.; Mitchell, M. M.; Ibbotson, D. A.; Jones, A. M.; Neal, G. T. *J. Chem. Soc., Perkin 2* **1984**, 217.
- (13) Barton, D. H. R.; Donnelly, D. M. X.; Finet, J.-P.; Guiry, P. *J. J. Chem. Soc., Perkin Trans. 1* **1991**, 2095.
- (14) Fielden, R.; Meth-Cohn, O.; Suschitzky, H. *J. Chem. Soc., Perkin Trans. 1* **1973**, 696.
- (15) Shim, S. C.; Doh, C. H.; Kim, T. J.; Lee, H. K.; Kim, K. D. *J. Heterocycl. Chem.* **1988**, *25*, 1383.
- (16) Stauffer, S. R.; Lee, S.; Stambuli, J. P.; Hauek, S. I.; Hartwig, J. F. *Org. Lett.* **2000**, *2*, 1423.
- (17) Birch, A. J.; Hutchinson, E. G.; Rao, G. S. *J. Chem. Soc. (C)* **1971**, 637.
- (18) Pearson, A. J.; Gelormini, A. M. *J. Org. Chem.* **1994**, *59*, 4561.
- (19) Jones, D. H. *J. Chem. Soc. (C)* **1971**, 132.